The correction refers to segment, market segment and clearing (market in bold below) effective as from November 24, 2016.
On request of Alligator Bioscience AB, company registration number 556597-8201, Nasdaq Stockholm AB has admitted the company’s shares to trading on Nasdaq Stockholm, with effect from November 23, 2016. The decision is conditional upon that Alligator Bioscience AB can meet the requirements regarding liquidity.
The company’s share capital consists of 59,244,384[1] shares as per today’s date.
| Short Name: | ATORX |
| Number of shares to be listed: | 70,013,615[2] |
| ISIN Code: | SE0000767188 |
| Order Book ID: | 129022 |
| Average Daily Turnover: | 750,000, EUR |
| Clearing: | CCP Cleared |
| Segment: | Mid Cap |
| Market segment: | STO Equities CCP / 182 |
| Tick Size Table: | Other Equities / 227 |
| MIC: | XSTO |
ICB Classification:
| Industry code: | 4000 Health care |
| Supersector code: | 4500 Health care |
When issued trading
Trading will be on a when issued basis from November 23 2016, up and including November 24, 2016, i.e. trading will begin before all conditions in the Offering has been satisfied and will cease if the Offering is not completed. For further information see page 25 in the prospectus (Sw. version).
For further information concerning this exchange notice please contact Issuer Surveillance, telephone +46 8 405 60 00, or iss@nasdaq.com.
[1] See prospectus page 75 (Sw. version)
[2] Provided that the Offering and over-allotment is fully utilized, see prospectus page 75 (Sw. version)